Improved Antitumor Efficacy of a Dextran-based Docetaxel-Coupled Conjugate Against Triple-Negative Breast Cancer

CONCLUSION: This dual-drug C-DDD has the potential to become a candidate for clinical application through the optimization of the linker.PMID:37349996 | DOI:10.2174/1567201820666230622105503

Source: Current Drug Delivery - June 23, 2023 Category: Drugs & Pharmacology Authors: Hongshuai Lv Weiping Jia Peng Dong Jiaojiao Liu Si Wang Xiaohai Li Jinghua Hu Ling Zhao Yikang Shi Source Type: research